MedPath

Boehringer Ingelheim USA Corporation

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

Efficacy and Safety of Eschscholtzia Californica in Treating Primary Insomnia

Phase 3
Terminated
Conditions
Sleep Initiation and Maintenance Disorders
Interventions
Drug: Eschscholtzia Californica
Drug: Eschscholtzia Californica Placebo
First Posted Date
2014-07-08
Last Posted Date
2014-07-08
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
49
Registration Number
NCT02183233

Bioequivalence Study of UH-AC 62 XX Tablets Compared With the Capsule Formulations in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: UH-AC 62 XX tablet
Drug: UH-AC 62 XX capsule
First Posted Date
2014-07-08
Last Posted Date
2014-07-08
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
22
Registration Number
NCT02181907

Bioavailability of BI 1356 and Glyburide in Healthy Male and Female Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: BI 1356 + Glyburide
First Posted Date
2014-07-08
Last Posted Date
2014-07-08
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
20
Registration Number
NCT02183428

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses of BI 1356 BS in Healthy Male Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: BI 1356 BS - intravenous
Drug: Placebo
Drug: BI 1356 BS - Tablet
First Posted Date
2014-07-08
Last Posted Date
2014-07-08
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
36
Registration Number
NCT02183298

Pharmacokinetics and Tolerability of Meloxicam Gel Compared to Meloxicam Tablets in Healthy Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2014-07-08
Last Posted Date
2014-07-08
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
12
Registration Number
NCT02183077

Study to Compare the the Analgesic Efficacy and Tolerability of Meloxicam Versus Placebo and Ibuprofen in the Treatment of Pain After Surgery of the Third Molar

First Posted Date
2014-07-08
Last Posted Date
2014-07-08
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
381
Registration Number
NCT02183051

Bioavailability of Ibuprofen Enantiomers Compared With Standard Brufen Sirup in Healthy Male Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2014-07-08
Last Posted Date
2018-08-31
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
24
Registration Number
NCT02182960

Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of BI 201335 NA in Healthy Male Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Placebo
First Posted Date
2014-07-08
Last Posted Date
2014-07-18
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
39
Registration Number
NCT02182362

Safety and Tolerability Study of BIBF 1120 as Intravenous Infusion and Absolute Bioavailability of BIBF 1120 as Soft Gelatine Capsule in Healthy Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: BIBF 1120 intravenous solution
Drug: Placebo ampoule
Drug: BIBF 1120 soft gelatine capsule
First Posted Date
2014-07-08
Last Posted Date
2014-07-18
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
30
Registration Number
NCT02182258

Single Rising Dose Study of BI 201335 ZW in Healthy Male Subjects

Phase 1
Terminated
Conditions
Healthy
Interventions
Drug: Placebo
Drug: BI 201335 ZW - single rising dose
First Posted Date
2014-07-08
Last Posted Date
2014-07-18
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
8
Registration Number
NCT02182271
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy